ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > clinical trial?

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Oct 17, 2023 10:51am

211 Views

Post# 35687096

RE:clinical trial?

At the H.C. Wainwright Conference held on sptember 12, Larry Altstiel mentioned that the Phase 1 study would PROBABLY start early October (listened to the webcast a few times to make sure I heard it right)

Seriously, you announce the start of a clinical study to begin in a few weeks and recruitment doesn't show up on any radar THEN and NOW a month later?

By all accounts (and Promis' track record of missed milestone target dates), it will be a miracle if the study actually begins in 2023.

Hopefully and wishfully, I will be proven wrong.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property